Content about Pharmaceutical drug

January 24, 2012

A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

PALATINE, Ill. — A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

Acura said it was informed by Pfizer that Oxecta has hit the market in 5-mg and 7.5-mg strengths, which will be sold in 100-count bottles. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

January 20, 2012

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

January 20, 2012

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


January 18, 2012

Patent expirations of key blockbuster drugs and efforts by payers to contain costs are likely to bring strong growth to the global generic drug market in the next few years as market-earned revenues grow by more than $100 billion, according to an analysis by research firm Frost & Sullivan.

LONDON — Patent expirations of key blockbuster drugs and efforts by payers to contain costs are likely to bring strong growth to the global generic drug market in the next few years as market-earned revenues grow by more than $100 billion, according to an analysis by research firm Frost & Sullivan.

The report, titled "Generic Pharmaceuticals Market — A Global Analysis" and focusing on the United States and Europe, also found that healthcare expenditure and sales revenues are poised to shift to India, China, Brazil, Turkey and South Korea.

January 11, 2012

Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.

ST. LOUIS — Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.

Fleming announced the sale of the OTC nasal spray Ocean, the prescription kidney dialysis vitamin supplement Nephrocaps, the magnesium supplement Magonate and ProBarimin QT, a medical food product for patients who have received weight loss surgery. Financial terms were not disclosed.

January 3, 2012

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said Tuesday.

January 3, 2012

Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said.

SUPPLIER NEWS — Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said. The features will give pharmacies an outreach channel to improve their bin management and will-call services, as well as allow them to easily identify aging prescriptions and use the Mscripts mobile application to remind customers to pick up their prescriptions.


December 23, 2011

Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

PHILADELPHIA — Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

The report, titled "The Changing Role of Chemistry in Drug Discovery" and based on drug industry productivity, patent data and other dynamics and trends, was released in recognition of the International Year of Chemistry 2011.

December 13, 2011

Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

NEW YORK — Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy's generic atorvastatin calcium tablets and Watson Pharmaceuticals' authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.

December 1, 2011

Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

NEW YORK — Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

The New York Times reported Thursday that three senators — Max Baucus, D-Mont.; Chuck Grassley, R-Iowa; and Herb Kohl, D-Wis. — had asked Pfizer and five other companies to provide details of their agreements to prevent dispensing of generic versions of Lipitor (atorvastatin) and dispense only the branded version.

November 4, 2011

In February, Drug Store News discussed three issues concerning generic drugs that would figure prominently throughout the year: drug safety, user fees and patent settlements.


In February, Drug Store News discussed three issues concerning generic drugs that would figure prominently throughout the year: drug safety, user fees and patent settlements.


November 2, 2011

It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

NEW YORK — It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

October 31, 2011

Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

PARSIPPANY, N.J. — Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

October 20, 2011

Insight Pharmaceuticals is voluntarily recalling one lot of a nasal decongestant due to the possibility of bacterial contamination, the company said.

LANGHORNE, Pa. — Insight Pharmaceuticals is voluntarily recalling one lot of a nasal decongestant due to the possibility of bacterial contamination, the company said.

Insight said it would recall lot number 11G075, UPC code 6373673005, of Nostrilla nasal spray to the consumer level because of possible contamination with Burkholderia cepacia bacteria. The lot, which contains 34,092 bottles, was distributed nationwide to retail outlets.

October 19, 2011

An amendment to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill that would prohibit the FDA from preventing an individual not in the business of importing a prescription drug from importing prescription drugs from Canada, has sparked concern with the National Association of Chain Drug Stores.

ALEXANDRIA, Va. — An amendment to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill that would prohibit the FDA from preventing an individual not in the business of importing a prescription drug from importing prescription drugs from Canada, has sparked concern with the National Association of Chain Drug Stores.

October 7, 2011

Anglo-Swedish drug maker AstraZeneca has settled patent infringement lawsuits that it filed against two companies that had sought to market generic versions of one of its drugs.

NEW YORK — Anglo-Swedish drug maker AstraZeneca has settled patent infringement lawsuits that it filed against two companies that had sought to market generic versions of one of its drugs.

The company settled with Handa Pharmaceuticals and also with Accord Healthcare and Intas Pharmaceuticals over two generic versions of the bipolar disorder and schizophrenia treatment Seroquel XR (quetiapine fumarate) extended-release tablets.

October 3, 2011

The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

The drug maker announced the approval of clindamycin injection, which the company said was the 12th product approved under its joint venture with Strides Arcolab, under which Strides is responsible for developing and supplying injectable products that Sagent markets in the United States.

The market for injectable clindamycin this year is about $65 million, according to IMS Health.

September 29, 2011

Last year, U.S. Customs and Border Protection seized $5.6 million worth of illegal pharmaceutical products, a 170% increase over 2005. Meanwhile, global sales of counterfeit medicines were estimated to be more than $75 billion last year, 90% more than in 2005. In response, Pfizer and the National Association of Boards of Pharmacy announced Thursday the launch of an effort to educate patients on how to safely buy medicines online and about the risks of counterfeit drugs.

NEW YORK — Last year, U.S. Customs and Border Protection seized $5.6 million worth of illegal pharmaceutical products, a 170% increase over 2005. Meanwhile, global sales of counterfeit medicines were estimated to be more than $75 billion last year, 90% more than in 2005.

In response, Pfizer and the National Association of Boards of Pharmacy announced Thursday the launch of an effort to educate patients on how to safely buy medicines online and about the risks of counterfeit drugs.

September 12, 2011


As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 



As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 


September 8, 2011

A group representing independent pharmacies is urging Congress to cut the deficit by reducing healthcare expenditures, but "without compromising patients' access to their pharmacy of choice or harming local jobs."

ALEXANDRIA, Va. — A group representing independent pharmacies is urging Congress to cut the deficit by reducing healthcare expenditures, but "without compromising patients' access to their pharmacy of choice or harming local jobs."

September 8, 2011

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

NEW YORK — Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

Citing Japan's Nikkei daily, Reuters reported that Gurgaon, India-based Ranbaxy would launch a generic version of Pfizer's cholesterol medication Lipitor (atorvastatin) at the end of November.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

September 1, 2011

The Food and Drug Administration has approved a generic skeletal muscle relaxant made by Sagent Pharmaceuticals, Sagent said.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic skeletal muscle relaxant made by Sagent Pharmaceuticals, Sagent said.

The generic drug maker announced the approval of orphenadrine citrate injection, which it will offer in 60-mg-per-2-mL, single-dose vials.

Various versions of the drug had sales of about $4.3 million in 2011, according to IMS Health.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


In May, Teva beat out Valeant’s $5.7 billion offer to buy Frazier, Pa.-based Cephalon with a $6.8 billion offer of its own, acquiring Cephalon’s hefty pipeline in the process. And last month, Teva bought Taiyo Pharmaceutical Industry, Japan’s third-largest generics company, for $934 million.


August 19, 2011

Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

Sagent announced the launch of vecuronium bromide, an injectable drug used to treat myasthenia gravis and Eaton-Lambert syndrome. The disorders cause muscle weakness and fatigue.

The market for vecuronium bromide is about $10 million in the United States, according to IMS Health.